Asthma: Symptoms, Causes, Types & Integrative Treatment NYC

Asthma

Asthma: Symptoms, Types, Causes & Integrative Treatment in NYC

Asthma is a chronic inflammatory disease of the bronchial airways in which the immune system overreacts to triggers—narrowing the airway, producing excess mucus, and causing the wheezing, chest tightness, and breathlessness that disrupt millions of lives daily. For many patients, conventional inhalers manage symptoms without ever addressing the underlying immune dysregulation, food sensitivities, gut-lung axis disruption, and environmental exposures that perpetuate airway inflammation—leaving them dependent on medication with no path toward resolution.

262M

People affected worldwide

~8%

Of US adults have asthma

3,500+

US deaths from asthma yearly

6–12 wks

Avg. time to see functional improvement

Medically reviewed by Dr. Rashmi Gulati, MD — Medical Director, Patients Medical.

Board-certified integrative medicine physician.

Clinical Definition

Asthma is a chronic inflammatory disease of the bronchial airways in which persistent eosinophilic or neutrophilic inflammation causes structural changes—including smooth muscle hypertrophy, goblet cell hyperplasia, and subepithelial fibrosis—that render the airways hyperresponsive to a wide variety of triggers. Episodic bronchoconstriction narrows the airway lumen and produces the hallmark triad of wheezing, chest tightness, and dyspnoea that is substantially or completely reversible either spontaneously or with pharmacological treatment. Functional medicine identifies asthma as a systemic inflammatory condition rooted in immune dysregulation, gut-lung axis disruption, environmental toxic burden, and nutritional insufficiencies that conventional spirometry and inhaler protocols do not address.

Key Symptoms

Wheezing on exhalation
Shortness of breath (dyspnoea)
Chest tightness or pressure
Chronic nocturnal cough
Exercise-induced breathlessness
Mucus hypersecretion

Primary Causes

Aeroallergen sensitisation (pollen, dust mites)
Vitamin D3 deficiency
Gut microbiome dysbiosis
Food intolerances (dairy, gluten)
Environmental pollutant exposure
Chronic stress / HPA axis dysfunction

Treatment Approach

Root-cause allergen & irritant elimination
Vitamin D3 & magnesium supplementation
Gut microbiome restoration protocol
Omega-3 fatty acids & quercetin
Buteyko breathing retraining
Targeted inhaler optimisation

What is Asthma?

Asthma is a chronic disease of the bronchial airways—the tubes that carry air into and out of the lungs—characterised by inflammation, mucus overproduction, and intermittent bronchospasm that make breathing laboured and, during severe episodes, frightening. Unlike a cold or respiratory infection, asthma does not go away; it is a persistent state of airway hypersensitivity that varies in severity from person to person and day to day. Many patients describe living in a state of constant low-level tightness punctuated by acute flares that force missed work days, emergency department visits, and a shrinking of daily life.

At the biological level, asthma involves a dysregulated immune response in the airway mucosa. In allergic (atopic) asthma—the most common form—inhaled allergens such as grass pollen, dust mite fecal particles, cat dander, or mold spores activate mast cells and Th2 lymphocytes, triggering the release of histamine, prostaglandins, and leukotrienes (particularly LTC4, LTD4, and LTE4). These inflammatory mediators cause the bronchial smooth muscle to contract (bronchoconstriction), the mucosal lining to swell (oedema), and mucus glands to overproduce thick secretions—together creating the narrowed, partially obstructed airway that produces wheezing and dyspnoea. In non-allergic asthma, the trigger is not IgE-mediated sensitisation but rather irritants, viral infections, exercise, cold air, or aspirin/NSAIDs that stimulate alternative inflammatory pathways involving neutrophils and IL-8 rather than eosinophils and IL-5.

Conventional medicine treats asthma primarily with inhaled corticosteroids (ICS) to suppress airway inflammation and short-acting beta-2 agonists (SABAs) such as albuterol for acute bronchoconstriction relief. These remain essential and life-saving tools. Functional medicine positions itself as a complementary framework that asks: what is driving this person’s immune system to overreact in the first place? Emerging evidence points to vitamin D deficiency impairing regulatory T-cell function, gut microbiome dysbiosis weakening mucosal immune tolerance via the gut-lung axis, undiagnosed food intolerances perpetuating systemic low-grade inflammation, and heavy metal accumulation exerting immunotoxic effects on airway mucosa. Identifying and correcting these upstream drivers does not replace bronchodilators—it creates conditions in which the airways become progressively less reactive over time.

Asthma affects approximately 25 million Americans and 262 million people globally, making it one of the most prevalent chronic non-communicable diseases worldwide. It affects children and adults of all ages, though it is approximately 1.6 times more common in adult women than adult men—a gap driven by hormonal influences on airway calibre and immune regulation. In New York City specifically, asthma disproportionately affects communities with higher environmental pollutant exposure, including diesel particulate matter, ozone, and indoor allergens in older housing stock—factors that Patients Medical’s integrative evaluation specifically investigates.

Bronchial Airways

The branching network of tubes (bronchi and bronchioles) that deliver air to the alveoli. In asthma, smooth muscle surrounding these tubes contracts abnormally in response to triggers, dramatically reducing internal diameter and airflow. Chronic inflammation leads to structural remodelling—thickening of airway walls that reduces capacity over time.

Bronchial Mucosa

The epithelial lining of the airways, which serves as the first barrier between inhaled air and the immune system. In asthma, goblet cells within this layer proliferate abnormally, producing excess mucus. The subepithelial layer becomes infiltrated with eosinophils and mast cells that maintain a state of chronic low-level inflammation even between acute episodes.

Mast Cells & Th2 Lymphocytes

The primary immune effector cells in allergic asthma. Mast cells, primed by allergen-specific IgE antibodies, degranulate upon allergen exposure—releasing histamine, prostaglandin D2, and leukotrienes that trigger the acute asthma response. Th2 lymphocytes sustain the inflammatory cycle by secreting IL-4, IL-5, and IL-13, cytokines that drive eosinophil recruitment, IgE production, and goblet cell hyperplasia.

Signs & Symptoms of Asthma

Asthma symptoms extend well beyond the airways—because chronic airway inflammation elevates systemic inflammatory cytokines, disrupts sleep, and alters immune function, patients often experience a constellation of respiratory, physical, cognitive, and emotional symptoms that can make diagnosis confusing.

Respiratory & Airway Symptoms

Wheezing

A high-pitched whistling sound on exhalation produced when airflow is forced through narrowed bronchioles; the hallmark acoustic sign of bronchospasm and the most widely recognised asthma symptom.

Shortness of Breath (Dyspnoea)

Perceived difficulty moving air—caused by increased airway resistance during bronchoconstriction—that is often worse with exertion, cold air, or during allergen exposure.

Chest Tightness

A sensation of pressure, constriction, or squeezing across the chest generated by sustained bronchial smooth muscle contraction and suboptimal air exchange in the lower lobes.

Chronic Cough

A persistent dry or mildly productive cough—often worse at night or early morning—driven by airway hypersensitivity and excess mucus stimulating cough receptors in the bronchial epithelium.

Excess Mucus Production

Goblet cell hyperplasia within the bronchial mucosa leads to thick, sticky secretions that further narrow airways, impair mucociliary clearance, and increase susceptibility to secondary bacterial respiratory infections.

Sleep & Nocturnal Symptoms

Nocturnal Waking

Circadian cortisol rhythms cause natural bronchodilation to be lowest between 2 and 4 AM, coinciding with the body's highest mast cell degranulation activity—making nighttime and early morning the most common periods for asthma attacks.

Early-Morning Chest Tightness

The post-nocturnal dip in endogenous adrenaline (epinephrine) and cortisol removes natural bronchodilator tone, often causing asthmatic patients to wake with significant chest tightness before their first bronchodilator dose.

Chronic Fatigue from Disrupted Sleep

Recurrent nocturnal awakenings fragment slow-wave and REM sleep architecture, producing daytime fatigue, cognitive impairment, and reduced immune competence that further impairs asthma control.

Sleep Apnea Overlap

Airway inflammation in asthma increases upper airway collapsibility and is independently associated with a two-fold higher prevalence of obstructive sleep apnea, creating a vicious cycle of nocturnal hypoxia, airway swelling, and morning exhaustion.

Reduced Daytime Energy

Systemic pro-inflammatory cytokines (IL-4, IL-5, IL-13, TNF-alpha) from chronic airway inflammation suppress mitochondrial energy production and promote central nervous system fatigue independent of sleep quality.

Physical & Exertional Symptoms

Exercise-Induced Bronchoconstriction (EIB)

Vigorous physical activity—especially in cold, dry air—increases ventilation rate, drying and cooling bronchial mucosa and triggering mast cell degranulation and bronchospasm typically peaking 5 to 10 minutes after cessation of exercise.

Reduced Exercise Capacity

Fear of triggering episodes combined with true airway limitation progressively reduces a patient's willingness and ability to engage in physical activity, creating a cycle of deconditioning that worsens overall cardiorespiratory fitness.

Rapid Respiratory Rate (Tachypnoea)

During acute bronchoconstriction, increased respiratory rate attempts to compensate for reduced tidal volume—but this shallow breathing pattern further reduces oxygen delivery and can trigger panic responses.

Hyperinflation (Air Trapping)

Obstructed exhalation prevents full emptying of the lungs, causing progressive air trapping that distends the thoracic cage, places the diaphragm at mechanical disadvantage, and increases the work of breathing substantially.

Voice Changes and Throat Clearing

Post-nasal drip associated with allergic rhinitis (extremely common in asthma patients), combined with vocal cord irritation from chronic coughing, produces hoarseness, throat clearing, and a sensation of mucus in the upper airways.

Cognitive, Emotional & Systemic Symptoms

Anxiety and Panic During Episodes

Acute breathlessness activates the amygdala's threat-detection system, generating a fear response that paradoxically worsens bronchoconstriction via sympathetic nervous system activation; research shows asthma patients have twice the population rate of anxiety disorders.

Cognitive Fog and Concentration Difficulty

Chronic systemic inflammation and sleep fragmentation impair prefrontal cortical function, reducing working memory, sustained attention, and executive processing—symptoms frequently reported by patients but rarely attributed to their asthma by conventional providers.

Eczema and Skin Flares (Atopic March)

Asthma is one component of the atopic triad alongside allergic rhinitis and atopic dermatitis (eczema); a shared Th2-skewed immune profile means that patients with one condition frequently manifest the others, particularly during high pollen seasons or dietary allergen exposure.

Frequent Respiratory Infections

Impaired mucociliary clearance, reduced secretory IgA in the airways, and corticosteroid-induced local immunosuppression increase susceptibility to viral and bacterial upper and lower respiratory infections, which are also the most common trigger for severe asthma exacerbations.

The 4 Types of Asthma: Intermittent, Mild, Moderate & Severe

Understanding your asthma type—classified by the frequency and severity of symptoms and the degree of airflow limitation on spirometry—is essential to calibrating the appropriate treatment intensity, identifying when step-up therapy is needed, and tracking whether your condition is improving over time.

01 Intermittent Asthma

FEV1 ≥ 80% predicted

Symptoms occur two days per week or fewer, with nighttime awakenings two times per month or fewer, no limitation of normal activities, and lung function at or near normal between episodes. Short-acting beta-2 agonist (SABA) use for symptom control is infrequent. This is the mildest classification, and patients in this category represent the strongest candidates for functional medicine interventions that address root causes before the condition progresses—typically including allergy testing, vitamin D optimisation, and dietary assessment.

02 Mild Persistent Asthma

FEV1 ≥ 80% predicted

Symptoms occur more than twice weekly but not daily, with nighttime awakenings three to four times per month, minor limitations on some activities, and FEV1 still above 80% of predicted value. SABA use is more frequent. This category warrants low-dose inhaled corticosteroid (ICS) therapy in conventional guidelines, and in the functional medicine framework, comprehensive root-cause investigation is most impactful here—gut microbiome testing, food intolerance panels, and environmental allergen mapping can meaningfully reduce the inflammatory burden driving the step-up from intermittent to persistent disease.

03 Moderate Persistent Asthma

FEV1 60–79% predicted

Daily symptoms with nighttime awakenings more than once weekly, some activity limitation, FEV1 between 60% and 79% of predicted, and daily SABA requirement. At this stage, structural airway remodelling may have begun, and conventional treatment requires medium-dose ICS often combined with a long-acting beta-2 agonist (LABA). Functional medicine contributes by reducing exacerbation frequency through precision trigger avoidance, anti-inflammatory supplementation (vitamin D3, omega-3s, quercetin), and breathing retraining—reducing the overall inhaler burden and improving quality of life.

04 Severe Persistent Asthma

FEV1 < 60% predicted

Continuous daily symptoms, frequent nighttime awakenings, severely limited physical activity, FEV1 below 60% of predicted value, and high SABA dependency. This category requires high-dose ICS-LABA combination therapy and may involve biologic agents (dupilumab, mepolizumab, benralizumab) targeting specific inflammatory pathways. Functional medicine plays a crucial adjunctive role—identifying persisting environmental exposures (mold, occupational allergens), optimising vitamin D levels, and supporting airway mucosal integrity through nutritional strategies while working in full collaboration with the patient’s pulmonologist.

Causes & Risk Factors for Asthma

Asthma rarely has a single cause. In most patients, it develops from a convergence of genetic susceptibility, immune dysregulation, environmental exposures, and nutritional deficiencies that together lower the threshold at which the airways overreact to otherwise harmless stimuli.

01

Aeroallergen Sensitisation

IgE-mediated sensitisation to house dust mites (Dermatophagoides pteronyssinus), grass pollens, tree pollens, cat and dog dander, and mold spores is the dominant driver of allergic asthma, present in approximately 50–70% of diagnosed cases.

02

Vitamin D3 Deficiency

Vitamin D receptors (VDR) are expressed on T-lymphocytes and mast cells; vitamin D insufficiency (25-OH-D below 30 ng/mL) impairs regulatory T-cell (Treg) development, reduces IL-10 production, and is independently associated with greater asthma severity and more frequent exacerbations.

03

Gut Microbiome Dysbiosis

Depletion of SCFA-producing bacteria (Lactobacillus, Bifidobacterium, Faecalibacterium prausnitzii) disrupts the gut-lung immune axis, reduces mucosal IgA, and promotes Th2 immune polarisation that drives airway eosinophilia and IgE overproduction.

04

Food Intolerances

IgG-mediated delayed food sensitivities to dairy proteins (casein, whey), gluten, eggs, and soy maintain a state of low-grade systemic inflammation that lowers the asthmatic airway’s trigger threshold and can directly produce mucus hypersecretion in sensitised individuals.

05

Air Pollution & Diesel Exhaust Particles

Fine particulate matter (PM2.5) and diesel exhaust particles directly damage bronchial epithelium, activate toll-like receptors on airway macrophages, and promote oxidative stress—mechanisms that both initiate asthma in susceptible children and worsen established disease in adults.

06

Mold Exposure

Airborne mold spores, particularly Aspergillus fumigatus, Alternaria alternata, and Cladosporium species, are potent inhalant allergens; indoor dampness and mold in NYC housing stock is a significant but frequently overlooked asthma driver that standard allergy panels may not identify.

07

Chronic Psychological Stress

Prolonged activation of the HPA axis elevates glucocorticoid receptor insensitivity in immune cells—a process called glucocorticoid resistance—that paradoxically perpetuates rather than suppresses airway inflammation despite high cortisol levels.

08

GERD (Gastro-oesophageal Reflux)

Microaspiration of gastric acid into the lower trachea and bronchi directly stimulates vagal reflexes, triggers cough and bronchospasm, and perpetuates airway mucosal inflammation—present in up to 75% of asthma patients as a bidirectional, treatment-modifiable comorbidity.

09

Occupational Exposures

Workplace inhalation of isocyanates (spray painters), flour dust (bakers), latex (healthcare workers), formaldehyde, and reactive dyes accounts for approximately 15% of adult-onset asthma cases—termed occupational asthma—where removal from exposure is the primary intervention.

10

Heavy Metal Accumulation

Mercury, cadmium, and arsenic accumulate in bronchial tissue and exert immunotoxic effects by inhibiting regulatory T-cell function, promoting Th2 cytokine production, and increasing oxidative stress in airway epithelial cells—a connection rarely evaluated in conventional asthma workups.

11

Genetic Susceptibility (ADAM33, ORMDL3)

Polymorphisms in genes including ADAM33 (encoding a bronchial epithelial metalloprotease), ORMDL3 (regulating airway remodelling at chromosome 17q21), and FCER1A (encoding the high-affinity IgE receptor) collectively confer significant heritable asthma risk in genetically tested individuals.

12

Viral Respiratory Infections in Early Life

Rhinovirus and respiratory syncytial virus (RSV) infections in infancy programme the bronchial mucosal immune response toward a Th2-dominant, pro-inflammatory pattern; children who experience severe viral bronchiolitis before age two have a four-fold increased lifetime risk of developing asthma.

Asthma vs. Related Conditions

Asthma shares symptoms with several other respiratory and systemic conditions; accurate differential diagnosis ensures patients receive targeted rather than generic treatment. The table below highlights the key distinguishing clinical and laboratory features.

Feature	Asthma	COPD	Allergic Rhinitis	Vocal Cord Dysfunction
Key Biomarker	Elevated FeNO; elevated blood eosinophils; elevated IgE	Reduced FEV1/FVC <0.70 post-bronchodilator; elevated neutrophils	Elevated allergen-specific IgE; nasal eosinophilia	Normal spirometry; paradoxical vocal cord adduction on laryngoscopy
Best Diagnostic Test	Spirometry with bronchodilator reversibility + FeNO	Post-bronchodilator spirometry	ImmunoCAP RAST or skin prick allergy testing	Flexible laryngoscopy during symptoms
Hallmark Symptom	Episodic wheezing & dyspnoea; reversible with bronchodilator	Progressive, irreversible exertional dyspnoea; chronic productive cough	Sneezing, rhinorrhoea, nasal congestion; no lower airway obstruction	Inspiratory stridor; sensation of throat tightness; normal PFTs
Standard Blood Test Detection	May show eosinophilia (>300/μL) and elevated total IgE	May show polycythaemia; ABG shows hypoxaemia in severe disease	Elevated total and specific IgE; possible eosinophilia	Normal CBC; normal IgE; anxiety markers may be elevated
Treatment Approach	ICS ± LABA; allergen avoidance; root-cause functional evaluation	LAMA bronchodilators; smoking cessation; pulmonary rehabilitation	Intranasal corticosteroids; antihistamines; allergen immunotherapy	Speech therapy; cognitive-behavioural therapy; breathing retraining
Overlap with Asthma	—	Asthma-COPD Overlap Syndrome (ACOS) in older/smoking patients	Present in 80% of asthma patients; treating rhinitis improves asthma control	Frequently misdiagnosed as exercise-induced asthma; may coexist

Important clinical note: Allergic rhinitis is present in up to 80% of asthma patients, and treating nasal inflammation with intranasal corticosteroids (such as fluticasone propionate) is strongly associated with improved lower airway control—a concept called the “unified airway.” If your asthma is poorly controlled despite appropriate inhaler use, untreated rhinitis should be evaluated.

How We Diagnose Asthma in NYC at Patients Medical

Asthma diagnosis at Patients Medical goes far beyond confirming airflow obstruction. Our comprehensive evaluation identifies the specific inflammatory drivers, allergen sensitivities, nutritional deficiencies, and environmental exposures unique to each patient—building a precision roadmap for root-cause treatment.

01 Spirometry with Bronchodilator Reversibility Testing

Spirometry measures FEV1 (forced expiratory volume in one second) and FVC (forced vital capacity). An FEV1/FVC ratio below 0.75 confirms obstructive ventilatory defect; improvement of FEV1 by ≥12% and ≥200mL after albuterol (salbutamol) administration confirms reversibility—the defining characteristic of asthma versus fixed obstruction as seen in COPD. We also assess the FEF25–75% (mid-expiratory flow) to detect small airway involvement that FEV1 alone can miss. This test is available in our NYC office and takes approximately 30 minutes.

02 Fractional Exhaled Nitric Oxide (FeNO) Testing

FeNO is a non-invasive breath test that directly measures eosinophilic airway inflammation—the primary inflammatory phenotype in allergic asthma. A FeNO level above 25 ppb (adults) or 35 ppb (children) indicates significant type 2 airway inflammation and predicts a favourable response to inhaled corticosteroid therapy. Critically, FeNO also quantifies treatment response over time, providing objective evidence of improving or persisting airway inflammation as our functional interventions take effect—something symptom scores alone cannot provide.

03 Comprehensive IgE & IgG Food Intolerance Panel

Standard IgE RAST testing identifies immediate hypersensitivity to common food and environmental allergens (pollens, dust mites, pet dander, mold species, latex). We supplement this with an IgG food intolerance panel—testing 96 to 200 foods—to identify delayed-onset food sensitivities that perpetuate systemic inflammation without producing immediate allergic reactions. Dairy products (casein and whey fractions), wheat gluten, eggs, soy, and corn are the most common IgG triggers in asthma patients seen at our practice.

04 25-Hydroxyvitamin D Serum Level & Micronutrient Assessment

25-hydroxyvitamin D (25-OH-D) is the standard serum measure of vitamin D status. Optimal levels for asthma control are above 50 ng/mL; most patients present at 20–35 ng/mL, placing them in clinically significant insufficiency. We additionally assess serum magnesium (RBC magnesium is more accurate than serum magnesium for evaluating intracellular stores), omega-3 index, and zinc—nutrients with specific, evidence-based roles in bronchial smooth muscle function, mast cell stability, and mucosal immunity.

05 GI-MAP Comprehensive Stool Analysis (Gut-Lung Axis Evaluation)

The GI-MAP (Gastrointestinal Microbial Assay Plus) uses quantitative PCR to identify specific bacterial species, parasites, fungi (including Candida albicans), and intestinal inflammation markers (calprotectin, zonulin for intestinal permeability). In asthma patients, we specifically look for depletion of SCFA-producing bacteria (Faecalibacterium prausnitzii, Akkermansia muciniphila, Bifidobacterium species) and overgrowth of pro-inflammatory species that dysregulate systemic immune responses via the gut-lung axis. Patients with concurrent digestive symptoms, history of antibiotic use, or severe allergic disease are prioritised for this assessment.

Does This Sound Like You?

Check the symptoms that apply to help us understand your experience:

I wheeze or feel breathless, especially at night or with exercise
I rely on my reliever inhaler more than twice a week
My asthma symptoms are worse in certain locations, seasons, or after eating
I wake at night with chest tightness or coughing
I've been told I have allergies, eczema, or hay fever as well as asthma
My asthma has not been well-controlled despite using prescribed inhalers
I've experienced significant digestive issues alongside my asthma symptoms
I feel exhausted even when my breathing is not actively bad
I've never had a comprehensive root-cause evaluation for my asthma

Asthma Treatment at Patients Medical NYC

At Patients Medical, asthma treatment begins with a personalised root-cause analysis—not a prescription pad. Our integrative approach works alongside your existing inhaler regimen to systematically reduce the inflammatory burden, strengthen immune regulation, and create conditions in which your airways become progressively less reactive over time.

Precision Nutritional Supplementation

Based on comprehensive laboratory testing, we prescribe therapeutic doses of evidence-based nutrients that directly address the biological mechanisms of asthma. Vitamin D3 with K2 (typically 5,000–10,000 IU daily) restores Treg function and reduces exacerbation frequency. Magnesium glycinate (400mg nightly) relaxes bronchial smooth muscle and reduces hyperresponsiveness. Omega-3 fatty acids (EPA/DHA, 2–4g daily) shift the prostaglandin balance toward anti-inflammatory resolvins and protectins.

Vitamin D3/K2

Magnesium Glycinate

EPA/DHA Fish Oil

Quercetin

N-Acetylcysteine

Butterbur Extract

Elimination Diet & Food Sensitivity Protocol

Following IgG food intolerance testing, we implement a structured 6-to-12-week elimination and reintroduction protocol removing the patient’s specific reactive foods—most commonly dairy, gluten, eggs, and soy. This approach reduces the systemic inflammatory load that lowers the airway’s trigger threshold, allowing the body to recalibrate its immune response. We provide detailed dietary guidance, meal planning resources, and regular monitoring to ensure nutritional adequacy throughout the process.

IgG Elimination Protocol

Anti-Inflammatory Diet

Mediterranean Pattern

FODMAP Consideration

Gut Microbiome Restoration Therapy

Using GI-MAP stool analysis findings to guide precision probiotic and prebiotic selection, we rebuild the microbial communities responsible for producing SCFA butyrate and propionate—the gut metabolites that programme regulatory T-cells and dampen airway Th2 inflammation via the gut-lung axis. Therapeutic strains include Lactobacillus rhamnosus GG, Bifidobacterium longum, and spore-based Bacillus coagulans, combined with prebiotic fibre from arabinogalactan, partially hydrolysed guar gum, and inulin.

L. rhamnosus GG

Bifidobacterium longum

Arabinogalactan Prebiotic

Saccharomyces boulardii

Buteyko Breathing Retraining

The Buteyko technique is a structured breathing rehabilitation method developed by Dr. Konstantin Buteyko that reduces chronic hyperventilation—a pattern common in asthmatic patients that lowers carbon dioxide (CO₂) levels, causing reflex airway constriction. Buteyko training teaches nasal breathing, breath-hold exercises (control pauses), and reduced breathing volume patterns that restore optimal CO₂ levels, reduce airway smooth muscle tone, and significantly decrease SABA use. Multiple randomised controlled trials demonstrate 50–70% reduction in bronchodilator use with consistent Buteyko practice.

Buteyko Method

Nasal Breathing Training

CO₂ Tolerance Exercises

Control Pause Protocol

Acupuncture for Airway Inflammation

Traditional Chinese medicine acupuncture targeting Lung meridian points (LU7 Lieque, LU9 Taiyuan, ST36 Zusanli) has demonstrated in clinical trials to reduce airway hyperresponsiveness, lower serum IgE concentrations, decrease FeNO levels, and improve FEV1 in asthmatic patients when administered in a course of 10 to 15 sessions. The proposed mechanism involves modulation of the autonomic nervous system—shifting from sympathetic to parasympathetic dominance—and reducing mast cell degranulation via neuropeptide regulation.

Lung Meridian Points

10–15 Session Course

Autonomic Modulation

Environmental Allergen & Toxin Remediation

Our physicians provide detailed, evidence-based environmental intervention plans personalised to the patient’s specific allergen sensitivities identified on testing. For dust mite-sensitive patients, interventions include mattress encasements, HEPA air filtration, and humidity reduction below 50%. For mold-sensitive patients, we coordinate mold testing referrals and assess for indoor mycotoxin exposures. For heavy metal-burdened patients, we initiate targeted chelation support using NAC, glutathione, and modified citrus pectin as appropriate.

HEPA Filtration

Mold Toxin Clearance

Heavy Metal Detox

Allergen Avoidance Plan

What to Expect: Your Recovery Timeline

Weeks 1–4	Comprehensive testing completed; dietary modifications and initial supplementation (vitamin D3, magnesium, omega-3s) begun; baseline spirometry and FeNO established. Most patients notice improved sleep quality and reduced nighttime symptoms within the first two to three weeks of dietary elimination.
Weeks 6–12	Gut microbiome protocol initiated based on GI-MAP results; Buteyko breathing training underway; FeNO retest typically shows 20–40% reduction; significant decrease in SABA rescue inhaler use for most patients.
Months 3–6	Sustained nutritional and microbiome support; allergen immunotherapy considered for strongly sensitised patients; objective spirometry improvements measurable; many patients achieve the next lower severity classification.
Months 6–12+	For patients with long-standing asthma and airway remodelling, continued protocol adherence produces incremental improvements; inhaler reduction is gradual and always supervised in collaboration with prescribing physicians.

Lifestyle Practices for Asthma Recovery

Daily lifestyle habits profoundly influence asthma severity—both by reducing inflammatory triggers and by strengthening the physiological systems that regulate immune responses. The following six practices are specific and mechanistically grounded, not generic wellness advice.

Practise Exclusive Nasal Breathing Daily

The nasal passages warm, humidify, and filter inhaled air—functions the mouth cannot replicate. Mouth breathing allows cold, dry, unfiltered air to directly contact bronchial mucosa, triggering mast cell degranulation and bronchospasm. Practise nasal breathing during all activities including sleep (use mouth tape if needed); during the day, perform 10-minute sessions of light nasal breathing exercises, consciously reducing breathing rate to 8–12 breaths per minute to raise CO₂ tolerance and reduce airway smooth muscle tone.

Practise Daily Parasympathetic Activation

Chronic sympathetic nervous system dominance (the stress response) increases bronchial smooth muscle tone and promotes Th2 immune polarisation. Counteract this with 15 minutes of daily parasympathetic activation: 4-7-8 breathing (inhale 4 seconds, hold 7, exhale 8), box breathing, or diaphragmatic breathing in a supine position. Research demonstrates that daily coherence breathing at 5 breaths per minute significantly reduces airway hyperresponsiveness and cortisol-driven mast cell reactivity within four to six weeks of consistent practice.

Choose Swimming or Warm Indoor Exercise

Exercise is essential for asthma patients despite the challenge of exercise-induced bronchoconstriction (EIB). Swimming is the most asthma-friendly aerobic exercise: the warm, humid air above the water surface minimises airway drying, and the prone position strengthens respiratory muscles. Pre-exercise warm-up protocols (6-to-8-minute light jogging followed by high-intensity 30-second sprints) have been shown to reduce EIB severity by inducing a refractory period of mast cell mediator depletion. Always carry a SABA and use it 10 to 15 minutes before exercise if prescribed for EIB prophylaxis.

Implement Allergen Reduction in Your Sleep Environment

The bedroom is the single most important microenvironment to optimise for asthma because patients spend 7 to 9 hours there breathing bedroom air. Specific actions: encase mattress, duvet, and pillows in allergen-impermeable microfibre covers; wash bedding weekly in water above 55°C to kill dust mites; maintain indoor humidity at 40 to 50% using a hygrometer and dehumidifier; install a HEPA air purifier rated for your bedroom's square footage (CADR ≥ 150 cfm); remove carpeting if possible and replace with hard flooring that does not harbour dust mite colonies.

Prioritise Sleep Consistency & Circadian Rhythm

Asthma symptom severity follows a strong circadian pattern—worst between 2 and 4 AM due to physiological cortisol and adrenaline nadirs. Maintaining consistent sleep and wake times (±30 minutes) strengthens the cortisol awakening response, which provides natural bronchodilator tone in the early morning. Aim for 7 to 9 hours in a dark, cool (16–18°C), and allergen-controlled environment. Avoid blue-light screen exposure within 90 minutes of sleep to protect melatonin production, which has direct anti-inflammatory effects on airway mast cells.

Eliminate All Airway Irritant Exposures

Cigarette smoke—including second-hand and third-hand (smoke residue on surfaces)—is the single most harmful airway irritant for asthma patients and dramatically accelerates airway remodelling. Beyond smoking cessation, avoid: scented candles, incense, and plug-in air fresheners (which release volatile organic compounds including benzene and formaldehyde); gas cooktops without adequate ventilation (nitrogen dioxide is a potent airway irritant); and heavily fragranced cleaning products. Switch to fragrance-free cleaning agents and open windows when cooking to reduce PM2.5 buildup in the kitchen environment.

Diet & Nutrition Guide for Asthma

Diet is not a peripheral consideration in asthma management—it is a primary driver. The foods you eat daily either promote or suppress the eosinophilic airway inflammation, mast cell reactivity, and immune dysregulation that perpetuate asthma. A Mediterranean-pattern, anti-inflammatory diet rich in polyphenols, omega-3 fatty acids, and prebiotic fibres has been shown in prospective cohort studies to reduce asthma exacerbation frequency by up to 39%.

The Single Most Important Dietary Change:

Eliminate all dairy products—including milk, cheese, yoghurt, butter, and whey protein—for a minimum of 6 weeks. Dairy proteins (casein and whey) promote mucus hypersecretion in the respiratory tract and are the most commonly identified IgG food sensitivity in asthma patients at Patients Medical. Many patients report a dramatic reduction in baseline mucus burden, cough frequency, and morning chest tightness within the first two weeks of dairy elimination—even before other dietary changes are made.

Eat — Foods That Support Airway Recovery

Wild Salmon & Sardines: The richest dietary source of EPA and DHA omega-3 fatty acids that shift inflammatory prostaglandin balance from LTB4 to anti-inflammatory resolvins and protectins.
Turmeric (with Black Pepper): Curcumin inhibits NF-κB, the master transcription factor driving IL-4, IL-5, and IL-13 production in the bronchial mucosa; piperine from black pepper increases bioavailability 2,000%.
Dark Leafy Greens (Spinach, Kale): Rich in magnesium (critical for bronchial smooth muscle relaxation), folate, and antioxidant carotenoids that reduce oxidative stress in airway epithelial cells.
Apples & Onions: Primary dietary sources of quercetin—a flavonoid that stabilises mast cells, inhibits histamine release, and directly reduces leukotriene production in bronchial tissue.
Ginger: 5-Hydroxydecanoic acid in ginger inhibits phosphodiesterase-3 in airway smooth muscle, producing a bronchodilator effect; also reduces IL-6 and TNF-α production from activated macrophages.
Garlic: Organosulfur compounds (allicin, ajoene) in garlic have documented mast cell-stabilising and anti-inflammatory properties and support the gut microbiome's beneficial diversity.
Colourful Berries: Anthocyanins in blueberries, blackcurrants, and blackberries are potent anti-inflammatory polyphenols that reduce airway eosinophil accumulation and improve bronchial epithelial barrier integrity.
Fermented Foods (Kimchi, Kefir Alternatives): Non-dairy fermented foods introduce Lactobacillus and Bifidobacterium species that support gut microbial diversity and reinforce the gut-lung immune axis through SCFA production.
Brazil Nuts: The richest dietary source of selenium—a mineral essential for glutathione peroxidase activity, the primary antioxidant defence in airway epithelial cells exposed to inhaled oxidants.

Avoid — Foods That Worsen Asthma

All Dairy Products: Casein and whey promote mucus hypersecretion and are the most common IgG food trigger in asthma patients; even in the absence of frank dairy allergy, elimination typically reduces baseline mucus burden.
Sulphite-Containing Foods: Sulphites (E220–E228) in wine, dried fruits, processed meats, and pickled vegetables inhibit bronchial mucosal sulphite oxidase and trigger acute bronchospasm in up to 10% of asthma patients.
Processed Ultra-Refined Foods: High in omega-6 arachidonic acid precursors and advanced glycation end-products (AGEs) that directly activate NF-κB, amplifying the same pro-inflammatory pathways that drive airway eosinophilia.
Artificial Food Colourings: Tartrazine (Yellow No.5) and other azo dyes are established aspirin-sensitive asthma triggers that cross-react with leukotriene-generating pathways through COX enzyme inhibition.
Gluten (if IgG-Sensitive): For patients with confirmed wheat/gluten IgG sensitivity, gluten triggers systemic inflammatory responses and intestinal permeability that amplify the systemic inflammatory load driving airway reactivity.
Trans Fats and Hydrogenated Oils: Trans fatty acids (partially hydrogenated vegetable oils in commercial baked goods, margarine) directly increase leukotriene B4 production and reduce the bronchodilator response to beta-2 agonists.
High-Sodium Processed Foods: High dietary sodium intake is associated with increased airway hyperresponsiveness and more frequent asthma symptoms, potentially through osmotic effects on airway surface liquid and enhanced bronchomotor tone.
Sugar-Sweetened Beverages: Fructose in high quantities promotes low-grade systemic inflammation via NLRP3 inflammasome activation and impairs the gut microbiome's butyrate-producing bacterial community—both directly worsening asthma control.

Related & Overlapping Conditions

Asthma rarely exists in isolation. The same immune dysregulation and inflammatory drivers that produce airway hyperresponsiveness frequently manifest across multiple organ systems simultaneously—making comprehensive evaluation of these overlapping conditions essential for lasting asthma control.

Allergic Rhinitis

Present in 80% of asthma patients, allergic rhinitis involves the same IgE-mediated inflammation in the nasal mucosa that drives bronchial hyperresponsiveness—a “unified airway” in which untreated upper airway inflammation directly worsens lower airway control.

COPD

Chronic obstructive pulmonary disease produces irreversible airflow obstruction primarily from emphysema and chronic bronchitis; it shares dyspnoea and cough with asthma but differs fundamentally in its neutrophilic inflammation, fixed obstruction, and association with long-term smoking.

Eczema (Atopic Dermatitis)

Asthma, eczema, and allergic rhinitis form the atopic triad—three conditions sharing the same Th2-dominant immune phenotype, often appearing sequentially in the “atopic march” from infantile eczema to childhood asthma to adolescent hay fever.

Leaky Gut Syndrome

Intestinal hyperpermeability allows bacterial endotoxins (LPS) and undigested food antigens to enter the bloodstream, triggering systemic immune activation that amplifies airway eosinophilic inflammation via the gut-lung axis—a critical root-cause connection in many asthma patients.

GERD (Acid Reflux)

Present in up to 75% of asthma patients as a bidirectional comorbidity: acid microaspiration from GERD directly irritates bronchial mucosa and triggers cough and bronchospasm, while bronchodilators relax the lower oesophageal sphincter and worsen reflux.

Chronic Sinusitis

Persistent nasal and sinus inflammation directly drains post-nasal secretions into the lower airways, maintaining a state of chronic bronchial irritation; treating chronic sinusitis with nasal corticosteroids and targeted treatment is documented to reduce asthma exacerbation frequency.

When to See a Doctor About Your Asthma

Many asthma patients delay seeking help because they have normalised symptoms that are, in fact, signs of inadequate disease control—wheezing that is “just the way I am,” nightly awakenings that have become routine, or SABA dependency that feels unavoidable. If any of the following apply to you, a comprehensive functional medicine evaluation at Patients Medical can identify why your asthma is not responding as it should and map a personalised path toward better control.

Seek a Functional Medicine Evaluation If:

Use your reliever inhaler more than twice per week
Have been prescribed increasing doses of inhaled corticosteroids without improved control
Have concurrent digestive symptoms, skin rashes, or chronic fatigue alongside asthma
Experience significant anxiety or activity limitation due to fear of triggering episodes
Have tried multiple medications without achieving good asthma control.

Wake at night with asthma symptoms more than once a month
Notice asthma symptoms worsen after certain foods or in specific environments
Have never had testing for food sensitivities, vitamin D levels, or gut microbiome health
Have children with asthma and want to address the condition proactively at its root cause
Want to reduce your long-term dependence on pharmaceutical management

🚨 Seek Emergency Medical Evaluation Immediately if You Experience: Severe breathlessness that prevents you from completing a sentence, bluish colouration of the lips or fingertips (cyanosis), a peak flow reading below 50% of your personal best, use of your reliever inhaler with no improvement after 15 minutes, or a worsening acute asthma attack that does not respond to your prescribed action plan. Call 911 or proceed to your nearest emergency department without delay—acute severe asthma attacks can be life-threatening and require immediate hospital management with systemic bronchodilators and corticosteroids.

What Our Patients Say About Asthma Treatment at Patients Medical

Patient names have been abbreviated to protect privacy. Individual results vary; these accounts represent personal experiences and are not a guarantee of outcome.

"I had been on Advair for eight years and still waking up two or three nights a week with chest tightness. Dr. Gulati discovered I had severe dairy sensitivity and a major vitamin D deficiency—things no previous doctor had ever tested. Within six weeks of eliminating dairy and starting vitamin D and magnesium, I slept through the night for the first time in years. My FeNO dropped from 48 to 19 in three months. I still use my preventer inhaler but at a much lower dose."

"My 9-year-old son had been hospitalised twice in two years for severe asthma. We were desperate for answers beyond just more steroids. The team at Patients Medical ran a comprehensive evaluation and found significant gut dysbiosis, IgG sensitivity to wheat and eggs, and mold in our apartment. Six months after addressing all three, he hasn't had a single emergency visit, and his spirometry FEV1 improved by 18 percentage points. This approach changed our family's life."

"I'm a competitive runner who was told I'd have to manage exercise-induced asthma permanently with pre-workout albuterol. What no one had investigated was that my symptoms were dramatically worse in winter—Dr. Gulati connected this to both my vitamin D crashing seasonally and my mouth-breathing habit during runs. The Buteyko breathing training was a revelation. I now run half-marathons without any pre-exercise inhaler use. I wish I'd found this approach a decade earlier."

Explore Our Blog For More Insights

Frequently Asked Questions About Asthma

Is asthma a real medical condition, and what exactly is it?

Yes, asthma is a universally recognised, well-characterised chronic inflammatory disease of the bronchial airways. It affects approximately 262 million people worldwide and is one of the most prevalent chronic conditions in both children and adults. During asthma, the immune system overreacts to otherwise harmless triggers—including pollen, dust mite particles, pet dander, mold spores, cold air, or exercise—causing the smooth muscle surrounding the bronchial tubes to contract (bronchospasm), the mucosal lining to swell (oedema), and mucus glands to overproduce secretions. This triple response narrows the airway lumen and creates the characteristic difficulty breathing, wheezing, and chest tightness that patients experience.

In allergic asthma—the most common form—this process is mediated by IgE antibodies bound to mast cells, which degranulate upon allergen contact, releasing histamine, prostaglandins, and leukotrienes. In non-allergic asthma, the trigger is irritants (pollution, smoke), exercise, viral infections, or aspirin, operating through alternative inflammatory pathways. Spirometry with bronchodilator reversibility testing and fractional exhaled nitric oxide (FeNO) measurement are the gold-standard diagnostic tools that confirm both the presence and inflammatory phenotype of asthma.

Functional medicine views asthma as a systemic condition reflecting immune dysregulation that can be meaningfully addressed at its root—through vitamin D optimisation, gut microbiome restoration, food sensitivity elimination, and environmental toxin reduction—alongside, not instead of, conventional pharmaceutical management.

How long does asthma treatment take to show results at Patients Medical?

The timeline for meaningful asthma improvement through functional medicine depends on how long the condition has been present, its severity, and how quickly root-cause drivers are identified and addressed. Most patients begin noticing significant improvement within six to twelve weeks of beginning a personalised protocol.

In the first four weeks, comprehensive testing is completed—spirometry, FeNO, allergy panels, IgG food sensitivity, gut microbiome analysis, and vitamin D levels—followed by immediate dietary modifications (typically dairy elimination) and targeted supplementation including vitamin D3, magnesium glycinate, and omega-3 fatty acids. Many patients report improved sleep quality and reduced nighttime symptoms within two to three weeks of eliminating their specific food triggers.

By weeks six to twelve, gut microbiome restoration is underway, Buteyko breathing training produces measurable improvement in CO₂ tolerance, and FeNO retesting typically shows a 20 to 40% reduction in airway inflammation in responsive patients. At three to six months, objective spirometry improvements become measurable for most patients with mild to moderate asthma. For severe, long-standing asthma with structural airway remodelling, longer timelines of twelve to twenty-four months are realistic—with incremental improvements throughout. Medication reduction is always gradual and supervised collaboratively with the prescribing physician; we never ask patients to abruptly discontinue inhalers.

What tests does Patients Medical use to diagnose and evaluate asthma?

Our asthma evaluation begins with the clinical gold-standard tests and extends significantly into root-cause functional testing. Core diagnostic tests include: spirometry with bronchodilator reversibility testing (measuring FEV1, FVC, and FEV1/FVC ratio before and after albuterol to confirm reversible obstruction); and fractional exhaled nitric oxide (FeNO) testing, which directly measures eosinophilic airway inflammation and serves as an objective treatment response monitor over time.

For root-cause investigation, we conduct: a comprehensive IgE RAST or ImmunoCAP allergy panel identifying sensitisation to common aeroallergens (house dust mites, pet dander, pollens, mold species) and foods; an IgG food intolerance panel testing 96 to 200 foods to identify delayed-onset sensitivities to dairy, gluten, eggs, soy, and other common triggers; serum 25-hydroxyvitamin D level (with optimal target above 50 ng/mL for asthma control); RBC magnesium to assess intracellular magnesium status; omega-3 index to quantify EPA/DHA insufficiency; and GI-MAP comprehensive stool analysis for gut microbiome evaluation in patients with significant allergic disease, concurrent digestive symptoms, or history of frequent antibiotic use.

In appropriate patients, we also consider heavy metal testing via blood or urine provocation challenge, particularly for patients with significant environmental exposures or treatment-resistant asthma.

Can asthma cause fatigue, weight gain, and other non-respiratory symptoms?

Yes—while asthma is classified as a respiratory disease, its systemic inflammatory burden and the physiological consequences of chronic breathlessness produce a wide range of non-respiratory symptoms that are frequently under-recognised. Fatigue is one of the most common complaints: the chronic airway inflammation in asthma elevates pro-inflammatory cytokines including IL-4, IL-5, IL-13, and TNF-alpha, which directly impair mitochondrial energy production and promote central nervous system fatigue. Recurrent nocturnal symptoms chronically fragment sleep architecture, compounding daytime exhaustion.

Weight gain can result from multiple asthma-related mechanisms: long-term oral or high-dose inhaled corticosteroid use promotes visceral fat accumulation and insulin resistance; physical activity restriction due to exercise-induced bronchoconstriction reduces energy expenditure; and systemic inflammation dysregulates leptin and adiponectin signalling, promoting an obesogenic metabolic state. Importantly, obesity itself worsens asthma by mechanically reducing lung volumes, increasing airway inflammation through adipokine production, and worsening GERD—creating a bidirectional relationship.

Other non-respiratory symptoms commonly reported by asthma patients include cognitive fog and concentration difficulties (from sleep disruption and systemic inflammation), anxiety and panic (from the psychological experience of breathlessness), skin conditions such as eczema (sharing the same Th2 immune phenotype), and frequent respiratory infections (from impaired mucociliary clearance). A functional medicine evaluation addresses these systemic manifestations alongside the airway-specific pathology, producing improvements across all affected systems simultaneously.

What is the difference between asthma and COPD?

Asthma and chronic obstructive pulmonary disease (COPD) are both obstructive airway diseases but differ fundamentally in their mechanisms, populations, reversibility, and long-term trajectories. Asthma is characterised by variable, episodic, largely reversible airflow obstruction driven primarily by eosinophilic or allergic inflammation; it commonly begins in childhood or early adulthood, and airflow obstruction improves significantly with bronchodilator administration—FEV1 typically improves by ≥12% and ≥200mL after albuterol.

COPD, encompassing chronic bronchitis and emphysema, is driven by neutrophilic inflammation and structural destruction of alveolar tissue (emphysema) and chronic mucus hypersecretion (chronic bronchitis), almost always caused by long-term cigarette smoke, occupational pollutant, or biomass fuel exposure. COPD produces irreversible airflow limitation—the post-bronchodilator FEV1/FVC ratio remains below 0.70 by definition, and there is no meaningful reversibility response. COPD typically manifests in adults over 40 with a significant smoking history.

A clinically important overlap syndrome—Asthma-COPD Overlap (ACO)—occurs in patients who exhibit features of both conditions simultaneously, particularly older adults with a history of childhood asthma who are also smokers. These patients have both eosinophilic and neutrophilic inflammation and require a combined treatment approach. At Patients Medical, spirometry, FeNO testing, and blood eosinophil counts are used together to distinguish between asthma, COPD, and ACO and personalise treatment accordingly.

How does the gut microbiome affect asthma severity?

The gut-lung axis is one of the most important and scientifically validated connections in modern asthma research. The gut microbiome—the trillions of bacteria, fungi, and archaea inhabiting the gastrointestinal tract—directly programmes the immune system’s inflammatory set point, and disruption of microbial balance (dysbiosis) is now recognised as a significant driver of airway hyperresponsiveness and allergic sensitisation.

The mechanism operates primarily through short-chain fatty acids (SCFAs): beneficial gut bacteria, particularly Lactobacillus rhamnosus, Bifidobacterium longum, and Faecalibacterium prausnitzii, ferment dietary fibre to produce butyrate, propionate, and acetate. These SCFAs directly stimulate the development of regulatory T-cells (Tregs) in the gut-associated lymphoid tissue—the immune cells responsible for suppressing excessive Th2-driven allergic responses. When dysbiosis depletes SCFA-producing species (commonly following antibiotic exposure, low-fibre Western diets, or early-life formula feeding), Th2 immune polarisation increases, driving the eosinophilic airway inflammation and IgE overproduction characteristic of allergic asthma.

Large epidemiological studies confirm that children raised on farms or with diverse early microbial exposure consistently show lower rates of asthma and atopy. At Patients Medical, GI-MAP stool analysis identifies specific microbial imbalances, and precision probiotic therapy combined with prebiotic-rich dietary changes and food intolerance elimination is integrated into every asthma treatment protocol. Patients with concurrent IBS, food sensitivities, or frequent antibiotic history are especially likely to benefit substantially from gut microbiome restoration.

What supplements and natural treatments support asthma recovery?

Several evidence-based nutritional interventions meaningfully support asthma management when used alongside physician-supervised conventional treatment. At Patients Medical, all supplementation is personalised to laboratory findings rather than prescribed generically. The most robustly supported agents include:

Vitamin D3 with K2: Vitamin D deficiency (25-OH-D below 30 ng/mL) is strongly associated with increased asthma severity and exacerbation frequency. Supplementation to achieve serum levels above 50 ng/mL restores regulatory T-cell function and has been shown in randomised trials to reduce exacerbation rates by up to 30% in deficient patients. Typical therapeutic doses range from 5,000 to 10,000 IU daily, with K2 (MK-7) to guide calcium to bone rather than soft tissue.

Magnesium Glycinate (400mg nightly): Magnesium is required for bronchial smooth muscle relaxation; intracellular magnesium deficiency—extremely common and not detected by standard serum magnesium—is independently associated with airway hyperresponsiveness. Intravenous magnesium sulphate is standard emergency care for severe acute attacks; oral magnesium glycinate provides ongoing bronchomotor stability.

Omega-3 Fatty Acids (EPA/DHA, 2–4g daily): Shift the arachidonic acid inflammatory cascade away from pro-inflammatory leukotriene B4 production toward anti-inflammatory resolvins and protectins, directly reducing eosinophilic airway inflammation. Quercetin (500–1,000mg twice daily): A flavonoid with potent mast cell-stabilising, antihistamine, and leukotriene-inhibiting properties. N-Acetylcysteine (600mg twice daily): Supports glutathione synthesis, reduces airway oxidative stress, and has mucolytic properties that improve mucus clearance. Butterbur (Petasites hybridus) standardised extract: Has clinical trial evidence as a natural leukotriene modifier—use only PA-free certified products for safety.

Ready to Understand Your Asthma?

Most asthma patients have never had a comprehensive root-cause evaluation. At Patients Medical, we go beyond spirometry and inhalers to find—and address—the specific drivers of your airway inflammation, giving you a precise, personalised pathway toward lasting respiratory health.

Call us at (212) 794-8800 · 800 Second Avenue, Suite 900, New York, NY 10017

Begin Your Journey with Patients Medical

Patients Medical specializes in gently helping the patient identify the root cause of their medical issues and then assist them to recover from their problems to help them move forward to good health.

Request your consultation today!

To schedule an in person on Tele-medicine appointment, please call our office at (212) 794-8800 or email us at info@PatientsMedical.com We look forward to hearing from you

Our medical center in New York City.

Patients Medical PC
1148 Fifth Avenue, Suite 1B New York, NY 10128

Make an Appointment

TreatmentsTesting

Please leave this field empty.